SCHEMBL9895740

SCHEMBL9895740

CC=C(C(=O)OC)c1ccccc1COc1cc(F)cc(OCc2ccc([N+](=O)[O-])cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.48
HIF1A Q16665 4/20 0.46
MAOA P21397 1/20 0.45
MAPT P10636 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 3/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NTSR1 P30989 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
OPRL1 P41146 1/20 0.41
PLA2G1B P04054 1/20 0.40
ATG4B Q9Y4P1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9895742 0.93 MAOB (0.46) MAOBHIF1AMAOAMAPTSMN1; SMN2
SCHEMBL9895737 0.93 MAOB (0.46) MAOBHIF1AMAOAMAPTSMN1; SMN2
SCHEMBL9895739 0.93 MAOB (0.46) MAOBHIF1AMAOAMAPTSMN1; SMN2
SCHEMBL9894315 0.88 HIF1A (0.57) MAOBHIF1AMAPTSMN1; SMN2LMNA
SCHEMBL9894171 0.81 HIF1A (0.50) HIF1APLA2G1BATG4B
SCHEMBL9894632 0.81 HIF1A (0.48) HIF1AMAPTSMN1; SMN2LMNAL3MBTL1
SCHEMBL9894313 0.80 HIF1A (0.55) HIF1AMAPTLMNAMEN1KMT2A
SCHEMBL9894317 0.80 HIF1A (0.55) HIF1AMAPTLMNAMEN1KMT2A
SCHEMBL9894312 0.80 HIF1A (0.55) HIF1AMAPTLMNAMEN1KMT2A
SCHEMBL9895097 0.79 HIF1A (0.69) MAOBHIF1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US claimed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP claimed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US claimed
US-8772290-B2 Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same Oscotech Inc. (KR) 2014-07-08 US disclosed
EP-2565180-A2 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Oscotec Inc. (KR) 2013-03-06 EP disclosed
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME OSCOTEC INC. (KR) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149707-A1 ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME HIF1A, HIF1AN, EGLN3 MAOB 2441/4885HIF1A 1/4885MAOA 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.